Skip to main content

Table 1 Ruxolitinib dose modifications for safety

From: Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Patient status

Maximum ruxolitinib dose or action taken

Protocol-defined anemia*

5 mg BID

Platelet count 75 to < 100 × 109/L (inclusive)

10 mg BID

Platelet count 25 to < 75 × 109/L

5 mg BID

Platelet count < 25 × 109/L or ANC < 0.5 × 109/L

Interrupt administration

  1. ANC absolute neutrophil count, BID twice daily
  2. *For patients who were transfusion-dependent at baseline, anemia was defined as a ≥ 50% increase in transfusion frequency vs the transfusion frequency before day 1. For patients who were transfusion-independent at baseline, anemia was defined as (1) a ≥ 2 g/dL decline in hemoglobin to < 8 g/dL, unless not confirmed by repeat laboratory assessment within 7 days without an intervening change in dose, use of an erythropoiesis stimulant, or receipt of a transfusion; or (2) receipt of any transfusions (2 units minimum) in the previous 6-week period
  3. If protocol-defined anemia occurred at a dose of 5 mg BID (after, for example, a dose reduction for declining platelet counts), the dose could continue at 5 mg BID
  4. Patients already receiving 5 mg BID could continue at 5 mg BID with further declines in platelets to < 75 × 109/L and ≥ 25 × 109/L, but dosing was interrupted if platelet count was < 25 × 109/L